Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Completes Acquisition of RayThera Inc.
06:15pm, Thursday, 06'th Aug 2026
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on dis
Biogen Inc. $BIIB Shares Acquired by Amundi
04:21am, Saturday, 01'st Aug 2026
Amundi increased its stake in Biogen Inc. (NASDAQ: BIIB) by 38.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund own
Why Biogen Stock Topped the Market Today
07:23pm, Wednesday, 29'th Jul 2026
It handily beat analyst estimates on both the top and bottom lines. Investors didn't even mind a cut in adjusted net income guidance.
Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript
03:53pm, Wednesday, 29'th Jul 2026
Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
01:36pm, Wednesday, 29'th Jul 2026
Biogen Inc. (NASDAQ:BIIB) stock is trading higher on Wednesday after the company reported second-quarter adjusted earnings of $3.60 per share, beating the consensus of $2.96.
Q2 Earnings Season in Full Swing
12:31pm, Wednesday, 29'th Jul 2026
Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead o
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
12:10pm, Wednesday, 29'th Jul 2026
Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
Investors Await Fed Decision Today
11:45am, Wednesday, 29'th Jul 2026
A quarter-points rate hike has been bandied about as a possibility today.
Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)
11:29am, Wednesday, 29'th Jul 2026
Biogen Inc. is upgraded to 'Buy' as strategic acquisitions and pipeline progress offset multiple sclerosis portfolio erosion. Q2 revenue grew 3% Y/Y, aided by Apellis acquisition, rare disease, and Al
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:02am, Wednesday, 29'th Jul 2026
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street es
Biogen Q2 Earnings Call Highlights
10:05am, Wednesday, 29'th Jul 2026
Biogen NASDAQ: BIIB reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results.
Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates
08:31am, Wednesday, 29'th Jul 2026
Biogen Inc. (BIIB) came out with quarterly earnings of $3.6 per share, beating the Zacks Consensus Estimate of $3.04 per share. This compares to earnings of $5.47 per share a year ago.
Is Biogen Inc (BIIB) Overvalued After Q2 Earnings With EPS of $0.66 and Revenue of $2,736 Million? GF Score: 69/100
06:30am, Wednesday, 29'th Jul 2026
Biogen Inc (BIIB) released its 8-K filing on July 29, 2026, indicating notable performance in its recent quarter amid ongoing challenges in its legacy business.
Biogen Cuts FY Adjusted View as Profit Declines
06:23am, Wednesday, 29'th Jul 2026
Biogen's second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjusted earnings forecast.
Biogen beats quarterly estimates as newer drugs fuel growth
06:03am, Wednesday, 29'th Jul 2026
Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosi
